{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:42:31Z","timestamp":1792755751459,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6750,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1023\/a:1011160913619","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T06:26:45Z","timestamp":1040624805000},"page":"941-945","source":"Crossref","is-referenced-by-count":308,"title":["The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study"],"prefix":"10.1016","volume":"12","author":[{"given":"C.","family":"Waldherr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Maecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Haldemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mueller-Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1023\/A:1011160913619_bb0010","series-title":"Cancer: Principles & Practice of Oncology","first-page":"1706","article-title":"Carcinoid tumors and the carcinoid syndrome","author":"Jensen","year":"1997"},{"key":"10.1023\/A:1011160913619_bb0015","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0002-9610(79)90025-4","article-title":"The glucagonoma: Surgically curable diabetes","volume":"137","author":"Higgins","year":"1979","journal-title":"Am J Surg"},{"key":"10.1023\/A:1011160913619_bb0020","first-page":"125","article-title":"Clinical aspects of glucagon producing islet cell tumors","volume":"76","author":"Prinz","year":"1981","journal-title":"Am J Gastroenterol"},{"key":"10.1023\/A:1011160913619_bb0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00001622-199801000-00010","article-title":"Advances in chemotherapy and biotherapy of endocrine tumors","volume":"10","author":"Oeberg","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"10.1023\/A:1011160913619_bb0030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1011160913619_bb0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"Localization of endocrine related tumors with radioionated analogue somatostatin","volume":"1","author":"Krenning","year":"1989","journal-title":"Lancet"},{"key":"10.1023\/A:1011160913619_bb0040","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1056\/NEJM199011013231805","article-title":"Somatostatin receptor imaging in the localization of neuroendocrine tumors","volume":"323","author":"Lamberts","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1011160913619_bb0045","first-page":"1144","article-title":"New somatostatin analogs for SPET and PET","volume":"23","author":"B\u00e9h\u00e9","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1023\/A:1011160913619_bb0050","first-page":"18P","article-title":"DOTA-D-Phe(1)-Tyr(3)-octreotide (DOTATOC): A unique somatostatin receptor ligand for labeling with a variety of metallic radionuclides","volume":"38","author":"Maecke","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1023\/A:1011160913619_bb0055","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X","article-title":"Radiometal labeled macrocyclic chelator derivatised somatostatin analogue with superb tumor targeting properties and potential for receptor mediated internal radiotherapy","volume":"5","author":"Heppeler","year":"1999","journal-title":"Chem Eur J"},{"key":"10.1023\/A:1011160913619_bb0060","first-page":"792","article-title":"DOTATOC: A powerful new tool for receptor mediated radionuclide therapy","volume":"24","author":"Otte","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1023\/A:1011160913619_bb0065","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC. First clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1023\/A:1011160913619_bb0070","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s002590050268","article-title":"The somatostatin receptor-targeted radiotherapeutic [90Y]-DOTA-D-Phel-Tyr3-octeotide ([90Y]-SMT487) eradicates experimental rat pancreatic CA 20948 tumors","volume":"25","author":"Stolz","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1023\/A:1011160913619_bb0075","first-page":"368","article-title":"Yttrium-90 and indium-111 labeling, receptor binding and biodistribution of [90Y]-DOTA-D-Phel-Tyr3-octreotide, a promising somatostatin analogue for radionuclide therapy","volume":"24","author":"de Jong","year":"1997","journal-title":"Eur J Nucl Med"},{"issue":"8","key":"10.1023\/A:1011160913619_bb0080","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s002590050462","article-title":"Biokinetics and dosimetry in patients administered with 111ln-Tyr3-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC","volume":"26","author":"Cremonesi","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1023\/A:1011160913619_bb0085","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-3-642-80035-1_12","article-title":"Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system","volume":"142","author":"Faiss","year":"1996","journal-title":"Results Cancer Res"},{"key":"10.1023\/A:1011160913619_bb0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with long acting somatostatin analogue lanreotide: A prospective study in 39 patients","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"},{"issue":"1","key":"10.1023\/A:1011160913619_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0002-9343(90)90127-Y","article-title":"Empiric chemotherapy in patients with carcinoma of unknown primary site","volume":"88","author":"Sporn","year":"1990","journal-title":"Am J Med"},{"issue":"8","key":"10.1023\/A:1011160913619_bb0100","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/sj.bjc.6690494","article-title":"Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin","volume":"80","author":"Johanson","year":"1999","journal-title":"BJC"},{"key":"10.1023\/A:1011160913619_bb0105","first-page":"68","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin","author":"Moertel","year":"1991","journal-title":"Cancer"},{"issue":"8","key":"10.1023\/A:1011160913619_bb0110","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1023\/A:1011160913619_bb0115","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3109\/07357909909032856","article-title":"Selective hepatic arterial chemoembolisation for liver metastases in patients with carcinoid tumor or islet cell carcinoma","volume":"17","author":"Kim","year":"1999","journal-title":"Cancer Invest"},{"issue":"5","key":"10.1023\/A:1011160913619_bb0120","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon. Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/7\/941\/19479547\/12-7-941.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:05:11Z","timestamp":1582164311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419541783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["S0923753419541783"],"URL":"https:\/\/doi.org\/10.1023\/a:1011160913619","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}